Hansa Biopharma Nomination Committee formed

LUND, Sweden, Dec. 13, 2023 /PRNewswire/ -- Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 29, 2023 and has the following composition:

• Florian Reinaoud representing Redmile Group
• Jonas Wikström representing Theodor Jeansson
• Sven Sandberg representing Thomas Olausson

As the conveyer of the Nomination Committee, Peter Nicklin, Chairman of the Board of Directors at Hansa Biopharma will be asked to summon the first meeting in the Nomination Committee.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.

The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2024 and will be published on Hansa Biopharma's website.

Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to ir@hansabiopharma.com or by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.

For further information, please contact:
Klaus Sindahl, VP Head of Investor Relations
M: +46 (0) 709–298 269
E: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
M: +1 (484) 319 2802
E: stephanie.kenney@hansabiopharma.com

The following files are available for download: